熱景生物(688068.SH):擬使用剩餘超募資金投建“全場景免疫診斷儀器、試劑研發與製造中心項目”
格隆匯 6 月 24日丨熱景生物(688068.SH)公佈,公司已於2020年6月23日召開第二屆董事會第十六次會議、第二屆監事會第十三次會議,審議通過了《關於使用剩餘超募資金投資建設“全場景免疫診斷儀器、試劑研發與製造中心項目”的議案》,該議案尚需提交公司股東大會審議。
“全場景免疫診斷儀器、試劑研發與製造中心項目”總投資預估為2億元(最終投資總額以實際投資為準),公司計劃使用剩餘超募資金6824.9萬元投入項目,不足部分公司自籌補足。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.